We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gantenerumab, Roche’s Anti-Amyloid Antibody, Snags Breakthrough Designation
Gantenerumab, Roche’s entry into the anti-amyloid antibody space, has secured FDA’s Breakthrough Therapy designation for treatment of Alzheimer’s disease (AD).